Artiva Biotherapeutics, Inc. (ARTV) stock
Close on Nov 12, 2026Market cap $193.61MP/E –Yield –
Artiva Biotherapeutics, Inc. saw revenue fall 100.0% to $0 over fiscal 2025. Free cash flow was -$86.60M. At the latest close the market valued the company at $193.61M.
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Sep 30, 2026
Valuation
- Market cap
- $193.61M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.60
- Dividend yield
- –
- Free cash flow yield
- -44.73%
Fundamentals
- Revenue
- $0
- Net income
- -$98.12M
- EPS, diluted
- -$2.99
- Free cash flow
- -$86.60M
- Book value per share
- $6.26
- Diluted shares
- 51M
Trading
- Next earnings
- Mar 9, 2027 (estimated, after the close)
- Previous close
- $4.07
- Open
- $4.05
- Day's range
- $3.93 – $4.09
- Volume
- 1,436,866
- Average volume (20 days)
- 1,345,492
- Index membership
- Russell 2000 (since Jun 2026)
- Beta (5 years)
- 2.31
- 52-week range
- $2.96 – $14.53
- RSI (14 days)
- 21.2
- Volatility (1 year)
- 138.6%
- Relative volume
- 2.38×
- WACC
- 16.4%
On 2 of our idea lists: Net-nets, More cash than they're worth
Index membership is inferred from the holdings of funds that track each index (IWM), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | ARTV | S&P 500 | Difference | ARTV per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -41.5% | -2.7% | −38.8 pts | ||
| 3 months | -65.7% | -1.7% | −63.9 pts | ||
| Year to date | -7.7% | +11.9% | −19.6 pts | ||
| 1 year | -0.5% | +12.0% | −12.5 pts |
Four years at a glance
Fiscal years 2022 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Artiva Biotherapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Results
- Results
About Artiva Biotherapeutics
Biological Products, (No Diagnostic Substances)
Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology company that develops natural killer cell therapies to treat autoimmune disorders. The company’s primary candidate is AlloNK, an investigational allogeneic natural killer cell therapy currently undergoing clinical development. This lead candidate targets diseases including lupus nephritis, systemic lupus erythematosus, rheumatoid arthritis, systemic sclerosis, Sjögren’s disease, and idiopathic inflammatory myopathies. Artiva also maintains early-stage discovery and preclinical programs, as well as collaborative partnerships. Because all assets remain in development, the company has no commercialized products or paying customers, directing its therapies toward patients suffering from autoimmune diseases.
Company profile, executives and historyArtiva Biotherapeutics stock: common questions
What is Artiva Biotherapeutics's stock price?
ARTV closed at $3.96 on Nov 12, 2026, down 2.70% on the day. Over the past 52 weeks it traded between $2.96 and $14.53.
What is Artiva Biotherapeutics's market cap?
Artiva Biotherapeutics was worth $193.61M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is ARTV's P/E ratio?
Artiva Biotherapeutics lost money over the twelve months to Sep 30, 2026 (diluted EPS -$2.99), so it has no meaningful P/E ratio.
How much revenue does Artiva Biotherapeutics make?
Artiva Biotherapeutics reported revenue of $0 for fiscal 2025, down 100.0% from a year earlier.
Does Artiva Biotherapeutics pay a dividend?
No. Artiva Biotherapeutics has not paid a cash dividend over the last twelve months.
When does Artiva Biotherapeutics report earnings next?
Artiva Biotherapeutics is expected to report Q4 FY2026 results on Mar 9, 2027, after the close. The date is estimated from its past reporting pattern until the company confirms it.
How has ARTV stock performed over the past year?
Including dividends, ARTV returned -0.5% over the past year, against +12.0% for the S&P 500.
How many ARTV shares are sold short?
3M shares were sold short at the latest FINRA report, 19.04% of the float, or 1.8 days of average trading volume.
Who are Artiva Biotherapeutics's competitors?
Companies most similar to Artiva Biotherapeutics by business, industry and size include ATYR, IMA, ABPO, AIM, CRDF.
See a number that looks wrong?